Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about where chemotherapy should be placed in patients with luminal breast cancer and an intermediate risk recurrence score.

He provides further details of this patient population and refers to the results from the TAILORx study, where adjuvant chemotherapy had no effect in this patient group.

Prof Gligorov also mentions that patients who are aged less or equal to 50 years with a risk recurrence score between 16 and 25 may benefit from chemotherapy.

He concludes by stating that patients above the age of 50 should not be given chemotherapy, but younger patients should.